Objective: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache. Material and methods: This was a retrospective single-center not funded study. Enrolled patients were affected by chronic migraine and medication overuse-headache treated with erenumab monthly, up to 1 year. At 1 year, patients were classified as good responders if they displayed a ≥50% reduction in the number of headache days per months compared to the baseline. Results: After 1 year, a significant improvement in the number of headache days per months, analgesic consumption, 6-items headache impact test, and migraine disability assessment questionnaire scores were obtained compared to the baseline. Patients who obtained a ≥50% reduction in the number of headache days per month compared to the baseline displayed a longer history of medication overuse-headache, a higher number of painkillers taken per month at the baseline and a higher number of failed preventive treatments in the past. Conclusions: Patients with longer medication overuse-headache duration, higher analgesic intake, and a higher number of previous preventive treatment failures may receive less benefit with erenumab.

Predictors of response to erenumab after 12 months of treatment / Baraldi, C.; Castro, F. L.; Cainazzo, M. M.; Pani, L.; Guerzoni, S.. - In: BRAIN AND BEHAVIOR. - ISSN 2162-3279. - 11:8(2021), pp. N/A-N/A. [10.1002/brb3.2260]

Predictors of response to erenumab after 12 months of treatment

Pani L.;
2021

Abstract

Objective: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache. Material and methods: This was a retrospective single-center not funded study. Enrolled patients were affected by chronic migraine and medication overuse-headache treated with erenumab monthly, up to 1 year. At 1 year, patients were classified as good responders if they displayed a ≥50% reduction in the number of headache days per months compared to the baseline. Results: After 1 year, a significant improvement in the number of headache days per months, analgesic consumption, 6-items headache impact test, and migraine disability assessment questionnaire scores were obtained compared to the baseline. Patients who obtained a ≥50% reduction in the number of headache days per month compared to the baseline displayed a longer history of medication overuse-headache, a higher number of painkillers taken per month at the baseline and a higher number of failed preventive treatments in the past. Conclusions: Patients with longer medication overuse-headache duration, higher analgesic intake, and a higher number of previous preventive treatment failures may receive less benefit with erenumab.
11
8
N/A
N/A
Predictors of response to erenumab after 12 months of treatment / Baraldi, C.; Castro, F. L.; Cainazzo, M. M.; Pani, L.; Guerzoni, S.. - In: BRAIN AND BEHAVIOR. - ISSN 2162-3279. - 11:8(2021), pp. N/A-N/A. [10.1002/brb3.2260]
Baraldi, C.; Castro, F. L.; Cainazzo, M. M.; Pani, L.; Guerzoni, S.
File in questo prodotto:
File Dimensione Formato  
Brain and Behavior - 2021 - Baraldi - Predictors of response to erenumab after 12 months of treatment.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 357.69 kB
Formato Adobe PDF
357.69 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1279826
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact